In the last decade, it has become increasingly clear that a gut full of friendly microbes (the microbiome) is vital for our good health. It has also become clear that a healthy microbiome is one with a diverse population of microbes (bacteria, viruses, fungi). What we haven’t known is why a diverse array of friendly bugs is important for keeping the harmful microbes (pathogens) at bay. But now we think we have found the answer.
Our latest study, published in Science, shows that the main reason a diverse microbiome is helpful for resisting pathogens is that the friendly microbes collectively consume the nutrients needed for a pathogen to grow in the gut.
In other words, a diverse microbiome blocks pathogen growth by using its nutrients – a phenomenon we call “nutrient blocking”. Understanding how nutrient blocking works is powerful because it allows us to predict which gut communities will be protective against a given pathogen.
Our research team started by conducting a large screen of 100 common strains of human gut bacteria. We tested the individual ability of these strains to restrict the growth of two bacterial pathogens, Klebsiella pneumoniae and Salmonella enterica serovar Typhimurium. These two species are a problem because many strains are becoming resistant to antibiotics.
Alone, the gut strains could not prevent pathogen growth. However, this was different when several of these species were pooled into larger communities. Higher diversity communities tended to offer more protection against invading pathogens, both in test-tube experiments and when tested in mice.
However, not all higher diversity communities tested restricted pathogen growth. Crucially, certain species must be present for a community to be protective.
We then went on to investigate the reason why. We compared the nutrients that could be consumed by each of the individual species with the nutrients consumed by the pathogens. We realised that certain gut species had a higher nutrient use overlap with the pathogens than other species.
Still, individually, the nutrient use overlap of even these key species with the pathogens was not high enough to block pathogen growth. But when we considered which nutrients the community as a whole can use, we found that the communities with the highest degree of overlap with the pathogens provided the most protection.
Suggesting treatments
This finding is important as it provides a route for the design of beneficial, probiotic communities that aim to boost the microbiome’s ability to resist colonisation by disease-causing pathogens.
We tested this idea by taking a set of 50 human gut species and predicting which combinations of species would be protective against a new pathogen: a drug-resistant Escherichia coli.

Some strains of E coli bacteria (seen here) cause us harm. CDC/Janice Haney Carr
We selected the communities that were predicted to be poor at blocking the growth of this pathogenic E coli isolate, and communities that were predicted to be good, and tested them against the new pathogen. In all cases, the nutrient blocking principle was able to successfully predict the ability of the community to block the growth of the pathogen.
Antibiotic treatment failure is becoming more common due to the spread of resistant pathogens. Alternative solutions that harness the body’s natural ability to resist disease, such as by tinkering with the microbiome’s composition, are becoming more attractive.
The gut microbiome is integral to our health, but it is very complex and therefore hard to understand. Our study provides a template for how one might rationally design probiotic communities to engineer microbiomes for better health.


France Keeps Top Health Alert as Officials Brace for Another Heatwave
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak
US Plans Kenya Ebola Quarantine Facility Amid Congo Outbreak
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks
3 clinical-grade skincare creams you really shouldn’t buy online
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 



